REFERENCES
1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315-74.
2. Jaber F, Cholankeril G, El-Serag HB. Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies. J Can Assoc Gastroenterol. 2024;7:331-45.
3. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J-FH. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106-16.
4. Li J, Liu Y, Zheng R, Qu C, Li J. Molecular mechanisms of TACE refractoriness: directions for improvement of the TACE procedure. Life Sci. 2024;342:122540.
5. Lapidot Y, Amir A, Nosenko R, et al. Alterations in the gut microbiome in the progression of cirrhosis to hepatocellular carcinoma. mSystems. 2020;5:e00153-20.
6. Zhang N, Gou Y, Liang S, et al. Dysbiosis of gut microbiota promotes hepatocellular carcinoma progression by regulating the immune response. J Immunol Res. 2021;2021:4973589.
7. Schneider KM, Mohs A, Gui W, et al. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat Commun. 2022;13:3964.
8. Huang M, Ji Q, Huang H, Wang X, Wang L. Gut microbiota in hepatocellular carcinoma immunotherapy: immune microenvironment remodeling and gut microbiota modification. Gut Microbes. 2025;17:2486519.
9. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39:1441-9.
10. Wang X, Zhang B, Jiang R. Microbiome interplays in the gut-liver axis: implications for liver cancer pathogenesis and therapeutic insights. Front Cell Infect Microbiol. 2025;15:1467197.
11. Li R, Liu J, Ye F, et al. Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC. J Hepatol. 2026;84:808-22.
12. Bian CF, Wang Y, Yu A, et al. Gut microbiota changes and biological mechanism in hepatocellular carcinoma after transarterial chemoembolization treatment. Front Oncol. 2022;12:1002589.
13. Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. J Hepatol. 2021;75:S67-81.
14. Wang J, He XD, Zhang YC. Antibiotic prophylaxis in transarterial therapy of hepatocellular carcinoma: a meta-analysis. Can J Gastroenterol. 2012;26:85-91.
